
Oncology NEWS International
- Oncology NEWS International Vol 4 No 1
- Volume 4
- Issue 1
Ethyol Approved for Use in the UK
WEST CONSHOHOCKEN, Pa--The Medicines Control Agency, the regulatory agency for the United Kingdom, has granted a product license for the marketing of Ethyol (amifostine), manufactured by U.S. Bioscience, Inc.
WEST CONSHOHOCKEN, Pa--The Medicines Control Agency, the regulatoryagency for the United Kingdom, has granted a product license forthe marketing of Ethyol (amifostine), manufactured by U.S. Bioscience,Inc.
Ethyol is a selective cytoprotective agent indicated for the reductionof neutropenia-related infection resulting from use of the combinationof cyclophosphamide (Cytoxan, Neosar) and cisplatin (Platinol)in patients with advanced ovarian carcinoma.
Approval of ethyol in this country suffered a set back when anadvisory committee failed to recommend it to the FDA.
Articles in this issue
about 31 years ago
MDs Fear Managed Care Equals Lower-Quality Careabout 31 years ago
Dallas Medical Center Launches Umbilical Stem Cell Projectabout 31 years ago
Navelbine Receives FDA Approval for Advanced Non-Small -Cell Lung Cancerabout 31 years ago
Assessment Tools Are Essential to Improve Management of Painabout 31 years ago
Undertreating Pain Costs Money in the Long Run, Physician Warnsabout 31 years ago
After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCIabout 31 years ago
EORTC Endometrial Ca Trial Challenges Findings From GOGabout 31 years ago
Heterosexual AIDS Cases Up Sharply, But Numbers Remain SmallNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


































